Overview

SAVES-IBD: Safety & Efficacy of Aspirin vs. Standard of Care for VTE Prophylaxis After IBD Surgery

Status:
Not yet recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
We aim to determine if aspirin 81 mg orally twice daily is effective and safe as an extended VTE chemoprophylaxis agent after major abdominal surgery for IBD patients. We will perform an open label trial of aspirin for VTE prophylaxis compared standard of care.
Phase:
Phase 3
Details
Lead Sponsor:
The Cleveland Clinic
Treatments:
Aspirin